Ceren Damla Durmaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ceren Damla Durmaz has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Halil Gürhan Karabulut
Department of Medical Genetics, Faculty of Medicine Ankara University Ankara Turkey
6 shared publications Hatice Ilgın Ruhi
Department of Medical Genetics Ankara University School of Medicine Ankara Turkey
4 shared publications- Ezgi Gokpinar Ili
Department of Medical Genetics, Ankara University, Ankara, Turkey
3 shared publications - Ayşe Boyvat
Ankara University, Faculty of Medicine
2 shared publications - Dilsu Dicle Erkan
Department of Medical Genetics, Ankara Etlik City Hospital 1 Turkey
2 shared publications Elifcan Taşdelen
Department of Medical Genetics, Ankara University School of Medicine, Ankara, Turkey
2 shared publications
Latest Publications
- 11 July 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 247
Tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa: a case-control study
- 11 July 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 247
Tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa: a case-control study
- Open Access
- 18 February 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (3) , 429-437
TMC6/8-associated epidermodysplasia verruciformis: germline variants and a complex structural alteration in a skin cancer predisposition syndrome
Hereditary epidermodysplasia verruciformis (EV) represents a paradigmatic inherited cutaneous syndrome linking viral susceptibility, immunity, and oncogenesis. Although biallelic variants in CIB1 , TMC6 , and TMC8 —encoding components of the keratinocyte-intrinsic antiviral complex—underlie most cases, the full mutational spectrum and its oncologic implications remain incompletely defined. We performed integrated genomic, histopathological, and longitudinal clinical analyses in six affected individuals from five unrelated families with confirmed hereditary EV. Comprehensive short-read sequencing, copy-number assessment, and optical genome mapping (OGM) were used to delineate the underlying genetic alterations, followed by long-range PCR and Sanger validation. Pathogenic or likely pathogenic germline variants affecting TMC6 or TMC8 were identified in all probands, providing molecular confirmation of disease. Four variants were novel, including splice-site, frameshift, and in-frame deletions. In one proband, OGM revealed a previously unrecognised complex del–inv–del structural variant spanning both TMC6 and TMC8 —the first reported example in hereditary EV. This rearrangement, confirmed at base-pair resolution, co-segregated with a synonymous TMC8 variant that served as a practical haplotypic marker for carrier testing. Clinically, all patients developed cutaneous squamous cell carcinoma (SCC), and several exhibited multifocal or aggressive disease, underscoring the deterministic malignant potential of hereditary EV. This study broadens the genetic and phenotypic spectrum of TMC6/TMC8 -associated EV, establishes complex structural rearrangement in the molecular etiology, and consolidates hereditary EV as a recessive cancer predisposition syndrome. Integrating high-resolution genome mapping into diagnostic workflows may uncover concealed allelic architecture in unresolved hereditary cancer syndromes.
- 18 February 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (3) , 429-437
Open AccessTMC6/8-associated epidermodysplasia verruciformis: germline variants and a complex structural alteration in a skin cancer predisposition syndrome
Hereditary epidermodysplasia verruciformis (EV) represents a paradigmatic inherited cutaneous syndrome linking viral susceptibility, immunity, and oncogenesis. Although biallelic variants in CIB1 , TMC6 , and TMC8 —encoding components of the keratinocyte-intrinsic antiviral complex—underlie most cases, the full mutational spectrum and its oncologic implications remain incompletely defined. We performed integrated genomic, histopathological, and longitudinal clinical analyses in six affected individuals from five unrelated families with confirmed hereditary EV. Comprehensive short-read sequencing, copy-number assessment, and optical genome mapping (OGM) were used to delineate the underlying genetic alterations, followed by long-range PCR and Sanger validation. Pathogenic or likely pathogenic germline variants affecting TMC6 or TMC8 were identified in all probands, providing molecular confirmation of disease. Four variants were novel, including splice-site, frameshift, and in-frame deletions. In one proband, OGM revealed a previously unrecognised complex del–inv–del structural variant spanning both TMC6 and TMC8 —the first reported example in hereditary EV. This rearrangement, confirmed at base-pair resolution, co-segregated with a synonymous TMC8 variant that served as a practical haplotypic marker for carrier testing. Clinically, all patients developed cutaneous squamous cell carcinoma (SCC), and several exhibited multifocal or aggressive disease, underscoring the deterministic malignant potential of hereditary EV. This study broadens the genetic and phenotypic spectrum of TMC6/TMC8 -associated EV, establishes complex structural rearrangement in the molecular etiology, and consolidates hereditary EV as a recessive cancer predisposition syndrome. Integrating high-resolution genome mapping into diagnostic workflows may uncover concealed allelic architecture in unresolved hereditary cancer syndromes.
- 30 September 2025
- Published by Ministry of Health, Ankara City Hospital in Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
- Vol. 22 (3) , 380-386
A Cross-Sectional Study of CHEK2 Pathogenic Variants: Cancer Risk Spectrum and Clinical Insights
Aims: CHEK2 is a tumor suppressor gene involved in DNA damage response and a moderate-risk gene for breast cancer. However, its role in other malignancies remains unclear, and the clinical impact of biallelic CHEK2 mutations is not well understood. This study aims to expand the cancer risk spectrum of CHEK2, including rare tumors, and to provide insights into the phenotypes associated with biallelic mutations and Multiple Inherited Neoplasia Alleles Syndrome (MINAS). Materials and Methods: We analyzed 40 individuals from 34 families carrying CHEK2 mutations, identified via multigene panel testing for hereditary cancer syndromes. Next-generation sequencing was performed for the probands, and segregation analysis in affected relatives was conducted using Sanger sequencing. Clinical data, including cancer type, age at diagnosis, and family history, were obtained from medical records and clinical evaluations. Results: We identified 16 distinct CHEK2 mutations, with c.1427C>T (p.Thr476Met) being the most frequent. Breast cancer was the most common diagnosis (75%), followed by thyroid cancer and rare tumors, including pancreatic neuroendocrine and cerebellopontine angle tumors. Multiple primary cancers occurred in 15% of patients, and 10% had MINAS, harboring additional variants in genes like PTEN and BRCA2. Biallelic CHEK2 mutations were linked to severe phenotypes, including bilateral breast cancer and adolescent-onset polyposis. Conclusions: Our findings broaden the CHEK2-associated cancer spectrum, extending beyond breast cancer to include rare malignancies and complex presentations. The identification of biallelic mutations and MINAS underscores the need for comprehensive genetic testing and tailored surveillance. These insights are crucial for refining risk assessment, enhancing prevention, and improving clinical management for individuals harboring CHEK2 mutations.
- 30 September 2025
- Published by Ministry of Health, Ankara City Hospital in Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
- Vol. 22 (3) , 380-386
A Cross-Sectional Study of CHEK2 Pathogenic Variants: Cancer Risk Spectrum and Clinical Insights
Aims: CHEK2 is a tumor suppressor gene involved in DNA damage response and a moderate-risk gene for breast cancer. However, its role in other malignancies remains unclear, and the clinical impact of biallelic CHEK2 mutations is not well understood. This study aims to expand the cancer risk spectrum of CHEK2, including rare tumors, and to provide insights into the phenotypes associated with biallelic mutations and Multiple Inherited Neoplasia Alleles Syndrome (MINAS). Materials and Methods: We analyzed 40 individuals from 34 families carrying CHEK2 mutations, identified via multigene panel testing for hereditary cancer syndromes. Next-generation sequencing was performed for the probands, and segregation analysis in affected relatives was conducted using Sanger sequencing. Clinical data, including cancer type, age at diagnosis, and family history, were obtained from medical records and clinical evaluations. Results: We identified 16 distinct CHEK2 mutations, with c.1427C>T (p.Thr476Met) being the most frequent. Breast cancer was the most common diagnosis (75%), followed by thyroid cancer and rare tumors, including pancreatic neuroendocrine and cerebellopontine angle tumors. Multiple primary cancers occurred in 15% of patients, and 10% had MINAS, harboring additional variants in genes like PTEN and BRCA2. Biallelic CHEK2 mutations were linked to severe phenotypes, including bilateral breast cancer and adolescent-onset polyposis. Conclusions: Our findings broaden the CHEK2-associated cancer spectrum, extending beyond breast cancer to include rare malignancies and complex presentations. The identification of biallelic mutations and MINAS underscores the need for comprehensive genetic testing and tailored surveillance. These insights are crucial for refining risk assessment, enhancing prevention, and improving clinical management for individuals harboring CHEK2 mutations.
- 3 December 2024
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (4) , e63945
Alu‐Mediated Deletion of FANCA in Turkish Families With Fanconi Anemia: Evidence of a Founder Effect
Fanconi anemia (FA) is a rare inherited bone marrow failure syndrome characterized by pancytopenia, increased susceptibility to malignancies, and a spectrum of congenital anomalies. Here, we report on eight affected individuals from six unrelated families with a large Alu‐mediated intragenic deletion encompassing exons 6–31 in the FANCA gene, identified as a founder mutation in the Turkish population through haplotype analysis. This deletion, mediated by Alu repeat sequences, underscores the role of repetitive elements in FA pathogenesis. Clinical data revealed variable phenotypic presentations among affected individuals, highlighting the challenge of establishing genotype–phenotype correlations even in the presence of identical FANCA pathogenic variants. We carried out an easy and effective PCR‐based diagnostic test for detecting this mutation, enabling precise diagnosis and genetic counseling for affected individuals and their families. This study provides valuable insights into the molecular mechanisms underlying FA pathogenesis and offers a practical approach for genetic diagnosis in affected individuals, particularly those of Turkish descent.
- 3 December 2024
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (4) , e63945
Alu‐Mediated Deletion of FANCA in Turkish Families With Fanconi Anemia: Evidence of a Founder Effect
Fanconi anemia (FA) is a rare inherited bone marrow failure syndrome characterized by pancytopenia, increased susceptibility to malignancies, and a spectrum of congenital anomalies. Here, we report on eight affected individuals from six unrelated families with a large Alu‐mediated intragenic deletion encompassing exons 6–31 in the FANCA gene, identified as a founder mutation in the Turkish population through haplotype analysis. This deletion, mediated by Alu repeat sequences, underscores the role of repetitive elements in FA pathogenesis. Clinical data revealed variable phenotypic presentations among affected individuals, highlighting the challenge of establishing genotype–phenotype correlations even in the presence of identical FANCA pathogenic variants. We carried out an easy and effective PCR‐based diagnostic test for detecting this mutation, enabling precise diagnosis and genetic counseling for affected individuals and their families. This study provides valuable insights into the molecular mechanisms underlying FA pathogenesis and offers a practical approach for genetic diagnosis in affected individuals, particularly those of Turkish descent.
- 13 May 2024
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 194 (9) , e63654
Filippi syndrome: Three new families suggest that urinary system abnormalities may belong to clinical spectrum of the disease
Filippi syndrome is a rare genetic disorder characterized by growth and neurodevelopmental delays, dysmorphism, and selective limb abnormalities. Although the syndrome was described approximately four decades ago, only a few families with molecularly confirmed diagnoses have been reported. In this article, we present three new patients of Filippi syndrome with unusual clinical and genetic aspects. These patients exhibited novel clinical features that have not previously been associated with Filippi syndrome, including renal hypoplasia/aplasia, renal cysts, renal cortical thinning, hypomelanotic, and hypermelanotic macules. All three patients had homozygous frameshift variants of the CKAP2L gene, specifically NM_152515.3: c.554_555del, c.981_982del, and c.1463_1467del, with the second being a novel variant. Given the limited number of reported Filippi syndrome patients to date and the ongoing discovery of new clinical aspects of the disease, exploring its potential connection with kidney and skin pigmentation abnormalities could be valuable for future research.
- 13 May 2024
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 194 (9) , e63654
Filippi syndrome: Three new families suggest that urinary system abnormalities may belong to clinical spectrum of the disease
Filippi syndrome is a rare genetic disorder characterized by growth and neurodevelopmental delays, dysmorphism, and selective limb abnormalities. Although the syndrome was described approximately four decades ago, only a few families with molecularly confirmed diagnoses have been reported. In this article, we present three new patients of Filippi syndrome with unusual clinical and genetic aspects. These patients exhibited novel clinical features that have not previously been associated with Filippi syndrome, including renal hypoplasia/aplasia, renal cysts, renal cortical thinning, hypomelanotic, and hypermelanotic macules. All three patients had homozygous frameshift variants of the CKAP2L gene, specifically NM_152515.3: c.554_555del, c.981_982del, and c.1463_1467del, with the second being a novel variant. Given the limited number of reported Filippi syndrome patients to date and the ongoing discovery of new clinical aspects of the disease, exploring its potential connection with kidney and skin pigmentation abnormalities could be valuable for future research.
- 6 April 2023
- Published by Turkish Academy of Sciences
- p. 741-772
Kanser ve Genetik
Cancer is a very heterogeneous group of diseases resulting from the interactions of genetic and environmental factors in terms of etiology. Enhanced knowledge of cancer genetics with rapidly developing genetic technologies, especially the next-generation sequencing systems, allows us to better understand the biology of cancer. Genetic studies in sporadic and hereditary cancers benefit many areas, including understanding the genetic etiology of cancer, identifying individuals at risk, making the correct diagnosis, determining and monitoring the patient's prognosis, using individualized treatment options, and developing new treatment modalities. Cancers arise due to the accumulation of genetic alterations within a cell. So that all cancers can be defined as genetic, but only a small portion of all cancers are inherited. The majority of genetic changes that lead to abnormal proliferation, clonal expansion, invasion of the cancer cells into surrounding tissues, and distant metastases are somatic alterations that occur during normal cell division and cannot pass on to offspring. However, some individuals with hereditary cancer syndromes have genetic changes that predispose them to an increased risk for certain cancers, and these changes can be passed on from one generation to the next. In this chapter, after briefly mentioning the basic principles in cancer genetics and mechanisms of molecular carcinogenesis, we discuss the genetic approach to hereditary cancer syndromes and describe hereditary cancer syndromes that are relatively common in the clinic in detail.
- 6 April 2023
- Published by Turkish Academy of Sciences
- p. 741-772
Kanser ve Genetik
Cancer is a very heterogeneous group of diseases resulting from the interactions of genetic and environmental factors in terms of etiology. Enhanced knowledge of cancer genetics with rapidly developing genetic technologies, especially the next-generation sequencing systems, allows us to better understand the biology of cancer. Genetic studies in sporadic and hereditary cancers benefit many areas, including understanding the genetic etiology of cancer, identifying individuals at risk, making the correct diagnosis, determining and monitoring the patient's prognosis, using individualized treatment options, and developing new treatment modalities. Cancers arise due to the accumulation of genetic alterations within a cell. So that all cancers can be defined as genetic, but only a small portion of all cancers are inherited. The majority of genetic changes that lead to abnormal proliferation, clonal expansion, invasion of the cancer cells into surrounding tissues, and distant metastases are somatic alterations that occur during normal cell division and cannot pass on to offspring. However, some individuals with hereditary cancer syndromes have genetic changes that predispose them to an increased risk for certain cancers, and these changes can be passed on from one generation to the next. In this chapter, after briefly mentioning the basic principles in cancer genetics and mechanisms of molecular carcinogenesis, we discuss the genetic approach to hereditary cancer syndromes and describe hereditary cancer syndromes that are relatively common in the clinic in detail.
- Open Access
- 7 November 2022
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 39 (6) , 422-428
Genetic Analysis of RASD1 as a Candidate Gene for Schizophrenia
Background: RASD1 encodes Dexamethasone-induced Ras-related protein 1 (Dexras1), a protein with a critical role in signal transduction in neurons. There is a strong suspicion that dysfunction of Dexras1 might contribute to the pathogenesis of neuropsychiatric diseases. Related to its functions in intracellular signaling pathways, Dexras1 has a potential role in the etiology of schizophrenia because of its close interaction with NOS1, NOS1AP, and NMDAR, which have previously been associated with schizophrenia. Aims: To investigate the association of RASD1 variants with schizophrenia in a selected cohort from Turkey. Study Design: A case-control study. Methods: We performed targeted sequencing for the two exons, single intron, and untranslated regions of RASD1 gene in 200 individuals with schizophrenia and 100 healthy controls of Turkish origin. Results: Two rare variants, RASD1 (NM_016084.5): c.722A>T and c*31G>A were identified in individuals with schizophrenia but not in any controls. The c.722A>T was found in a single individual with schizophrenia and is a missense heterozygous variant in the second exon of RASD1, which is extremely rare in GnomAD. The other variant, c*31G>A, which was found in another individual from this schizophrenia cohort, has not been reported previously. Seven previously identified common single nucleotide polymorphisms were also detected; however, they were not significantly associated with schizophrenia in this study cohort. Conclusion: Our findings suggest that rare variants ofRASD1 might be contributing to the etiopathogenesis of schizophrenia. Further studies are needed to elucidate the underlying mechanism of this association.
- 7 November 2022
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 39 (6) , 422-428
Open AccessGenetic Analysis of RASD1 as a Candidate Gene for Schizophrenia
Background: RASD1 encodes Dexamethasone-induced Ras-related protein 1 (Dexras1), a protein with a critical role in signal transduction in neurons. There is a strong suspicion that dysfunction of Dexras1 might contribute to the pathogenesis of neuropsychiatric diseases. Related to its functions in intracellular signaling pathways, Dexras1 has a potential role in the etiology of schizophrenia because of its close interaction with NOS1, NOS1AP, and NMDAR, which have previously been associated with schizophrenia. Aims: To investigate the association of RASD1 variants with schizophrenia in a selected cohort from Turkey. Study Design: A case-control study. Methods: We performed targeted sequencing for the two exons, single intron, and untranslated regions of RASD1 gene in 200 individuals with schizophrenia and 100 healthy controls of Turkish origin. Results: Two rare variants, RASD1 (NM_016084.5): c.722A>T and c*31G>A were identified in individuals with schizophrenia but not in any controls. The c.722A>T was found in a single individual with schizophrenia and is a missense heterozygous variant in the second exon of RASD1, which is extremely rare in GnomAD. The other variant, c*31G>A, which was found in another individual from this schizophrenia cohort, has not been reported previously. Seven previously identified common single nucleotide polymorphisms were also detected; however, they were not significantly associated with schizophrenia in this study cohort. Conclusion: Our findings suggest that rare variants ofRASD1 might be contributing to the etiopathogenesis of schizophrenia. Further studies are needed to elucidate the underlying mechanism of this association.
- 2 March 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (6) , 1792-1800
Phenotypic and molecular characterization of five patients with PIK3CA‐related overgrowth spectrum (PROS)
Somatic and germline PI3K‐AKT‐mTOR pathway pathogenic variants are involved in several segmental overgrowth phenotypes such as the PIK3CA‐related overgrowth spectrum (PROS), Proteus syndrome, and PTEN hamartoma tumor syndrome. In this study, we describe five patients with PROS. We identified by high‐throughput sequencing four different somatic PIK3CA pathogenic variants in five individuals. The Glu726Lys variant, which was previously reported in megalencephaly‐capillary malformation‐polymicrogyria (MCAP) syndrome, was identified in two patients with unclassified PROS. The Cys420Arg substitution, which was previously reported in CLOVES, was found in a patient with fibroadipose hyperplasia. Additionally, relatively rare pathogenic variants, His1047Tyr and Tyr1021Cys, were detected in two patients with MCAP. Therefore, we suggest performing deep sequencing of PIK3CA in all patients with suspected PROS, instead of targeted polymerase chain reaction for hotspot pathogenic variants.
- 2 March 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (6) , 1792-1800
Phenotypic and molecular characterization of five patients with PIK3CA‐related overgrowth spectrum (PROS)
Somatic and germline PI3K‐AKT‐mTOR pathway pathogenic variants are involved in several segmental overgrowth phenotypes such as the PIK3CA‐related overgrowth spectrum (PROS), Proteus syndrome, and PTEN hamartoma tumor syndrome. In this study, we describe five patients with PROS. We identified by high‐throughput sequencing four different somatic PIK3CA pathogenic variants in five individuals. The Glu726Lys variant, which was previously reported in megalencephaly‐capillary malformation‐polymicrogyria (MCAP) syndrome, was identified in two patients with unclassified PROS. The Cys420Arg substitution, which was previously reported in CLOVES, was found in a patient with fibroadipose hyperplasia. Additionally, relatively rare pathogenic variants, His1047Tyr and Tyr1021Cys, were detected in two patients with MCAP. Therefore, we suggest performing deep sequencing of PIK3CA in all patients with suspected PROS, instead of targeted polymerase chain reaction for hotspot pathogenic variants.
- 25 March 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (7) , 2267-2270
MASP1‐related 3MC syndrome in a patient from Turkey
3MC syndrome is a rare condition manifesting with typical facial appearance, postnatal growth deficiency, skeletal manifestations, and genitourinary tract anomalies. 3MC is caused by biallelic pathogenic variants in MASP1, COLEC11, or COLEC10. Here, we report an affected subject of Kurdish origin from Turkey presenting with facial dysmorphisms, such as, hypertelorism, blepharophimosis, blepharoptosis, highly arched eyebrows, umbilical hernia, and caudal appendage. These features were compatible with 3MC syndrome. Molecular analysis revealed a novel homozygous pathogenic variant, c.310C > T; p.Gln104Ter in the MASP1 gene, resulting in a premature stop codon. Few subjects with 3MC syndrome have been reported in the literature so far. Thus, detailed study of this subject contributes to the evolving clinical and genetic characterization of 3MC syndrome.
- 25 March 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (7) , 2267-2270
MASP1‐related 3MC syndrome in a patient from Turkey
3MC syndrome is a rare condition manifesting with typical facial appearance, postnatal growth deficiency, skeletal manifestations, and genitourinary tract anomalies. 3MC is caused by biallelic pathogenic variants in MASP1, COLEC11, or COLEC10. Here, we report an affected subject of Kurdish origin from Turkey presenting with facial dysmorphisms, such as, hypertelorism, blepharophimosis, blepharoptosis, highly arched eyebrows, umbilical hernia, and caudal appendage. These features were compatible with 3MC syndrome. Molecular analysis revealed a novel homozygous pathogenic variant, c.310C > T; p.Gln104Ter in the MASP1 gene, resulting in a premature stop codon. Few subjects with 3MC syndrome have been reported in the literature so far. Thus, detailed study of this subject contributes to the evolving clinical and genetic characterization of 3MC syndrome.